1. Baseline characteristics before and after propensity score matching.
Variables | Entire cohort (n = 710) | Matched cohort (n = 334) | |||||
Non-thrombocytopenia
(n = 461, DPC ≤ 50%) |
Thrombocytopenia
(n = 249, DPC > 50%) |
P-
value |
Non-thrombocytopenia
(n = 167, DPC ≤ 50%) |
Thrombocytopenia
(n = 167, DPC > 50%) |
P-
value |
||
Data are presented as n (%). *Presented as median (interquartile range). APACHE: Acute Physiology and Chronic Health Evaluation; DPC: drop in platelet count. | |||||||
Age, yrs | 65 (58−75)* | 67 (59.5−74)* | 0.235 | 66 (60−76)* | 68 (60−74)* | 0.827 | |
Male | 338 (73.3%) | 164 (65.9%) | 0.037 | 110 (65.9%) | 111 (66.5%) | 1.000 | |
Caucasian | 369 (80.0%) | 187 (75.1%) | 0.127 | 126 (75.4%) | 130 (77.8%) | 0.671 | |
Body mass index, kg/m2 | 29.06 (25.16−33.01)* | 27.95 (24.93−32.22)* | 0.113 | 28.7 (24.95−33.27)* | 27.66 (24.93−32.38)* | 0.318 | |
APACHE IVa score | 52 (38.25−76)* | 65 (43−98)* | < 0.001 | 60 (45−92)* | 61 (42−93)* | 0.544 | |
Mean arterial pressure, mm Hg | 76.33 (66.67−87.33)* | 76.83 (65.58−90.33)* | 0.724 | 76.33 (68−86.67)* | 77.67 (65.67−90.33)* | 0.679 | |
Cardiovascular risk factors | |||||||
Hypertension | 283 (61.4%) | 161 (64.7%) | 0.390 | 106 (63.5%) | 106 (63.5%) | 1.000 | |
Diabetes mellitus | 177 (38.4%) | 85 (34.1%) | 0.262 | 51 (30.5%) | 52 (31.1%) | 1.000 | |
Hypercholesterolemia | 52 (11.3%) | 26 (10.4%) | 0.733 | 20 (12.0%) | 19 (11.4%) | 1.000 | |
Renal insufficiency | 52 (11.3%) | 27 (10.8%) | 0.860 | 11 (6.6%) | 14 (8.4%) | 0.678 | |
Cardiac history | |||||||
Prior angina | 41 (8.9%) | 18 (7.2%) | 0.443 | 12 (7.2%) | 13 (7.8%) | 1.000 | |
Prior myocardial infarction | 100 (21.7%) | 55 (22.1%) | 0.903 | 41 (24.6%) | 41 (24.6%) | 1.000 | |
Prior percutaneous coronary intervention | 75 (16.3%) | 41 (16.5%) | 0.946 | 22 (13.2%) | 26 (15.6%) | 0.626 | |
Prior coronary artery bypass grafting | 34 (7.4%) | 20 (8.0%) | 0.753 | 8 (4.8%) | 13 (7.8%) | 0.359 | |
Prior congestive heart failure | 79 (17.1%) | 45 (18.1%) | 0.754 | 23 (13.8%) | 28 (16.8%) | 0.551 | |
Prior valve disease | 30 (6.5%) | 25 (10.0%) | 0.093 | 14 (8.4%) | 18 (10.8%) | 0.541 | |
History of vascular diseases | |||||||
Prior stroke/Transient ischemic attack | 31 (6.7%) | 18 (7.2%) | 0.800 | 7 (4.2%) | 11 (6.6%) | 0.481 | |
Prior peripheral vascular disease | 20 (4.3%) | 13 (5.2%) | 0.594 | 6 (3.6%) | 8 (4.8%) | 0.791 | |
Prior hemorrhage | 3 (0.7%) | 2 (0.8%) | 1.000 | 1 (0.6%) | 1 (0.6%) | 1.000 | |
Prior thrombosis | 20 (4.3%) | 11 (4.4%) | 0.961 | 7 (4.2%) | 7 (4.2%) | 1.000 | |
In-hospital cardiac diseases | |||||||
Angina | 45 (9.8%) | 26 (10.4%) | 0.773 | 21 (12.6%) | 20 (12.0%) | 1.000 | |
Myocardial infarction | 191 (41.4%) | 89 (35.7%) | 0.139 | 63 (37.7%) | 66 (39.5%) | 0.822 | |
Percutaneous transluminal coronary angioplasty | 234 (50.8%) | 142 (57.0%) | 0.110 | 92 (55.1%) | 92 (55.1%) | 1.000 | |
Coronary artery bypass grafting | 98 (21.3%) | 41 (16.5%) | 0.125 | 34 (20.4%) | 31 (18.6%) | 0.775 | |
Cardiogenic shock | 15 (3.3%) | 5 (2.0%) | 0.338 | 5 (3.0%) | 3 (1.8%) | 0.727 | |
Laboratory values | |||||||
Baseline platelet, × 109/L | 192 (147.25−237)* | 216 (165.5−257)* | 0.005 | 201(158−249)* | 215 (165−254)* | 0.978 | |
Baseline hemoglobin, g/dL | 12.40 (10.60−14.30)* | 12.40 (10.70−14.30)* | 0.767 | 12.3 (10.4−14.3)* | 12.2 (10.2−14.5)* | 0.862 | |
Baseline white blood cells, × 109/L | 12.00 (9.36−16.90)* | 13.00 (9.20−18.42)* | 0.202 | 12 (9.6−16.5)* | 13.2 (9.5−18.4)* | 0.583 | |
Baseline glucose, mmol/L | 8.06 (6.43−10.94)* | 8.64 (6.50−12.92)* | 0.037 | 8.39 (6.78−11.83)* | 8.39 (6.5−11.28)* | 0.739 | |
Baseline creatinine, mg/dL | 1.07 (0.87−1.35)* | 1.12 (0.90−1.52)* | 0.07 | 1.04 (0.84−1.27)* | 1.08 (0.87−1.49)* | 0.107 | |
Periprocedural medication | |||||||
Aspirin | 377 (81.8%) | 199 (79.9%) | 0.546 | 141 (84.4%) | 132 (79.0%) | 0.233 | |
Aggregation inhibitors | 168 (36.4%) | 75 (30.1%) | 0.090 | 58 (34.7%) | 56 (33.5%) | 0.913 | |
Glycoprotein IIB/IIIA inhibitor | 91 (19.7%) | 37 (14.9%) | 0.106 | 23 (13.8%) | 23 (13.8%) | 1.000 | |
Unfractionated heparin | 282 (61.2%) | 151 (60.6%) | 0.725 | 103 (61.7%) | 106 (63.5%) | 0.820 | |
Low molecular weight heparin | 95 (20.6%) | 63 (25.3%) | 0.151 | 42 (25.1%) | 38 (22.8%) | 0.683 | |
Warfarin | 45 (9.8%) | 38 (15.3%) | 0.030 | 20 (12.0%) | 20 (12.0%) | 1.000 | |
Fondaparinux | 1 (0.2%) | 6 (2.4%) | 0.015 | 1 (0.6%) | 1 (0.6%) | 1.000 | |
Thrombin inhibitor | 46 (10.0%) | 31 (12.4%) | 0.312 | 23 (13.8%) | 15 (9.0%) | 0.243 | |
Thrombolytic therapy | 3 (0.7%) | 6 (2.4%) | 0.099 | 1 (0.6%) | 1 (0.6%) | 1.000 |